GALECTIN THERAPEUTICS INC (GALT) Cash Flow Statement
GALECTIN THERAPEUTICS INC (GALT) generated -$15.9M of operating cash flow over the twelve months to 2026-06-30, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
GALTGALECTIN THERAPEUTICS INCFollow GALT — free
—
Price chart with a free account
- Market cap
- 321.7M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 16 Nov, in 23 days
| Line | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -5.7 | -7.5 | -7.5 | -12.4 | -17.0 | -16.4 | -15.9 | -10.2 | -10.8 | -20.6 | -24.3 | -31.1 | -33.0 | -41.8 | -23.9 | -15.9 | |
| Capital expenditure | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — | — | — | — | — | — | — | — | — | — | |
| Free cash flow | -5.7 | -7.5 | -7.5 | -12.4 | -17.0 | — | — | — | — | — | — | — | — | — | — | — | |
| Stock-based compensation | 3.2 | 2.8 | 3.8 | 4.1 | 3.4 | 2.5 | 1.1 | 4.4 | 1.7 | 1.8 | 2.1 | 2.9 | 2.3 | 2.4 | 1.7 | — |
USD millions · SEC XBRL
GALECTIN THERAPEUTICS INC — questions
- What is GALECTIN THERAPEUTICS INC's operating cash flow?
- -$15.9M over the twelve months to 2026-06-30.
Every figure on this page comes from GALECTIN THERAPEUTICS INC's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.